A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Trial details
- Registry ID
- NCT04702568
- Phase
- Phase 2
The FDA approved Eculizumab (Soliris) on 16 Mar 2007.
Drug identity checked against registry records
Also recorded as Soliris
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT04702568 | BioCryst Pharmaceuticals | Phase 2 | Terminated | 2023-10-04Actual |
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyNCT05116774 | BioCryst Pharmaceuticals | Phase 2 | Terminated | 2023-09-14Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2007-03-16Day | Eculizumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125166", "applicant_as_listed_by_fda": "ALEXION PHARM", "brand_names": ["SOLIRIS"], "active_ingredients": ["ECULIZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20070316", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |